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Abstract 1 
Four new mixed ligand dioxidomolybdenum(VI) [MoVIO2L1-3(Q)] (1‒3), [MoVIO2L4(Q)]2 2 
(H2O) (4) [where Q = MeOH for 1 and imidazole for 2‒4] complexes have been synthesized 3 
using four different ONO donor aroylhydrazone ligands (H2L1–4). All the derived ligands and 4 
complexes were characterised by IR, UV-Vis, NMR spectroscopy and CHNS-analysis while 5 
the redox properties of the complexes have been investigated by cyclic voltammetry. The 6 
molecular geometries of 1‒4 were established by X‒ray crystallography and are closely related 7 
to each other, having a cis-Mo(=O)2 core, a di-negative tridentate Schiff base ligand, which 8 
coordinates via the phenoxide-O1, amide-O4 and imine-N1 atoms, and with the sixth site 9 
occupied by an O-bound methanol molecule (1) or an N-bound imidazole molecule (2‒4); 4 10 
was isolated as a hydrate. The resultant NO5 (1) and cis-N2O4 (2‒4) donor sets are each based 11 
on a distorted octahedron. The complexes have been explored for their interaction with CT-12 
DNA, where moderate binding constants were observed in the range 103 to 104 M-1. The 13 
complexes showed different binding modes towards DNA such as intercalation, minor and 14 
major groove binding. Further, in vitro cytotoxicity activity of all the complexes were 15 
determined against HT-29 (colon cancer) and HeLa (cervical cancer) cell lines. Complex 4, 16 
due to the presence of a heterocyclic 2-hydroxy-1-naphthyl moiety in the ligand backbone, was 17 
found to be comparatively more potent than the other complexes. 18 
Keywords: Aroylhydrazone / Mixed ligand dioxidomolybdenum(VI) complexes / DNA 19 
binding/ Antiproliferative activity. 20 
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Introduction 1 
Molybdenum is one of the major trace elements found in daily diet and is also found in three 2 
different enzymes present in humans namely, sulfite oxidase, xanthine oxidase and aldehyde 3 
oxidase that have functions in detoxification [1-4]. It has been reported that the lack of the 4 
required amount of molybdenum can increase the risk of esophageal cancer [5]. Studies showed 5 
cell-growth inhibition properties of various polyoxidomolybdates on some specific carcinoma 6 
cells, among which Mo(II) complexes produce good cytotoxicity results. Though there are few 7 
reports on molybdenum complexes as anticancer agents [6,7], it has been found that with 8 
increased chelation in the structure there is a decrease in anticancer properties [8]. 9 
Molybdenum can also be considered a better replacement for cisplatin compared to other 10 
transition metals, due its labile nature and comparatively low cytotoxicity against non-11 
cancerous cells [9]. 12 
Molybdenum complexes of Schiff base ligands have gained significant interest owing to their 13 
low-cost and ease of preparation. Further, ligand preparation is basically facile: reacting 14 
sterically and electronically varied amines and aldehydes, respectively, through aldol 15 
condensation [10-20]. Schiff base ligands also have the potential to stabilize various metal ions 16 
in different oxidation states [21-25]. Moreover, the presence of a rigid, aromatic backbone 17 
provides specific spectroscopic properties that make transition metal complexes potential 18 
probes for nucleic acids. These metal complexes form intermediates in many enzymatic 19 
reactions that include the reaction of enzymes with amino or carbonyl group of the complex 20 
[26-40].  21 
Aryl hydrazones form a class of Schiff base organic scaffolds which show a wide range of 22 
biological properties including anticonvulsant and antituberculosis properties along with others 23 
like antibacterial, antifungal, antiinflammatory, antinociceptive and antiplatelet activities [41-24 
43]. Recently, Iproniazide, a hydrazone derived drug, has been used in the treatment of 25 
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tuberculosis [44].  Also, an oral nitrofuran antibiotic named Nifuroxazide is used for the 1 
treatment of anti-dehydration and for the treatment of colitis [45]. Furazolidone is a synthetic 2 
nitrofuran derivative that is well known for its antileishmanial activity and also clinically used 3 
as an antiprotozoal and antibacterial agent [46-50]. The advantageous electronic properties of 4 
arylhydrazones also give rise to complexes with more effective DNA-binding and DNA 5 
cleavage activities [27,32,34,35,37]. Molybdenum complexes of Schiff bases of aryl 6 
hydrazones are attractive due to their various applications including catalysis [51], luminescent 7 
probes [52], molecular sensors [53] and also display impressive biological activities [54-58] 8 
owing to the presence of the metal centre. On the other hand, as substituted imidazoles are 9 
found to have antiprotozoal, antifungal and antihypertensive properties [59-61], it has been 10 
employed as a co-ligand in the present study, in order to increase the overall biological potential 11 
of the synthesized complexes. 12 
In the past few years, our research group has investigated the synthesis of several transition 13 
metal complexes incorporating –ONO and –ONS donor ligand systems in order to explore 14 
their biological activity [24, 62-77].  In continuation of this work, herein we report four novel 15 
dioxidomolybdenum(VI) complexes with –ONO donor, aroylazine ligand systems (H2L1–4). 16 
All the complexes are characterized by various spectroscopic methods and their structural 17 
features have been elucidated by X-ray crystallography. Furthermore, the complexes have been 18 
evaluated for their DNA interaction activity which shows a moderate binding affinity. Finally, 19 
the in vitro antiproliferative activities of 1‒4 were assayed against the HT-29 (colon cancer) 20 
and HeLa (cervical cancer) cell lines and the mechanism of cell death for 4 ascertained by 21 
DAPI staining, i.e. apoptosis. 22 
 23 
 24 
 25 
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Experimental Section  1 
Materials and Methods 2 
The chemicals used herein were purchased from commercial sources, while the solvents were 3 
distilled under a dry nitrogen atmosphere according to the standard literature procedures [78, 4 
79] prior to use. [MoO2(acac)2] was used as the metal precursor and synthesized as per the 5 
reported procedure [79]. Elemental analysis (CHNS) measurements were carried out in a Vario 6 
EL cube elemental analyser instrument. FT–IR spectra were recorded by employing a Perkin 7 
Elmer Spectrum RX I spectrophotometer. Electronic spectra were recorded on a PerkinElmer 8 
Lambda 25 spectrophotometer. 1H and 13C NMR spectra where measured on a 400 MHz Bruker 9 
Ultrashield spectrometer with SiMe4 as the standard. CH-Instruments (model no. CHI6003E) 10 
electrochemical analyser was used to analyse the redox behaviour with Pt as the working and 11 
auxiliary electrodes, saturated calomel electrode (SCE) as the reference electrode and TBAP 12 
(tetrabutylammonium perchlorate) (0.1M) as the supporting electrolyte under a dry nitrogen 13 
atmosphere at 298 K. Calf thymus (CT) DNA (biochemistry grade) was procured from SRL 14 
(India), methyl green, ethidium bromide, Dulbecco’s phosphate buffered saline (DPBS), 15 
Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), trypsin EDTA 16 
solution and antibiotic‒antimitotic solution were procured from the Himedia (India). 3-[4,5-17 
Dimethylthiazol-2-yl]- 2,5-diphenyltetrazolium (MTT) and 4′,6-diamidino-2-phenylindole 18 
dihydrochloride (DAPI) were purchased from Sigma-Aldrich (India). For the DNA binding 19 
study, ultrapure water used for the biological assay was obtained through the purification 20 
system Millipore MilliQ Academic.  21 
Synthesis of ligands (H2L1–4) 22 
Substituted aryl hydrazone ligands H2L1–3 were prepared by the condensation of 3-ethoxy-2-23 
hydroxybenzaldehyde with the corresponding hydrazides [1-naphthoic hydrazide (H2L1), 2-24 
furoic hydrazide (H2L2) and 2-thiophenecarboxylic acid hydrazide (H2L3)], while, H2L4 was 25 
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obtained by the condensation of 2-hydroxy-1-naphthaldehyde with isonicotinic hydrazide in 1 
equimolar ratio in EtOH medium by following standard procedures [24,65,74]. The resulting 2 
compounds were then filtered, washed thoroughly with ethanol and dried over fused CaCl2 in 3 
a desiccator.  Elemental analysis results NMR (1H and 13C), UV-Vis and IR data verified their 4 
preparation. 5 
H2L1: Yield: 62%. Anal. calcd. for C14H14N2O4: C, 61.31; H, 5.14; N, 10.21. Found: C, 61.40; 6 
H, 5.36; N, 10.01. IR (KBr pellet, cm–1): 3336 ν(O–H); 2998 ν(N–H); 1657 ν(C=O); 1556 7 
ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 12.13 (s, 1H,–OH), 10.81 (s, 1H, NH), 8.65 (s, 1H, 8 
HC=N–), 7.97–6.72 (m, 6H, aromatic), 4.06 (m, 2H, –OCH2), 1.35 (t, 3H, –CH3). 13C NMR 9 
(100 MHz, DMSO-d6): δ 166.18 (CO–N), 159.18 (N=CH–), 152.36–113.59 (10C, aromatic), 10 
69.33 (–OCH2), 19.95 (–CH3). 11 
H2L2: Yield: 71%. Anal. calcd. for C20H18N2O3: C, 71.84; H, 5.43; N, 8.38. Found: C, 71.78; 12 
H, 5.42; N, 8.41. IR (KBr pellet, cm–1): 3392 ν(O–H); 3042 ν(N–H); 1657 ν(C=O); 1571 13 
ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 12.02 (s, 1H,–OH), 10.62 (s, 1H, NH), 9.13 (s, 1H, 14 
HC=N–), 8.02–6.97 (m, 10H, aromatic), 4.07 (m, 2H, –OCH2), 1.35 (t, 3H, –CH3). 13C NMR 15 
(100 MHz, DMSO-d6): δ 169.16 (CO–N), 158.67 (N=CH–), 154.16–118.21 (16C, aromatic), 16 
68.31 (–OCH2), 14.56 (–CH3). 17 
H2L3: Yield: 74%. Anal. calcd. for C14H14N2O3S: C, 57.92; H, 4.86; N, 9.65; S, 11.04. Found: 18 
C, 57.83; H, 4.91; N, 9.64; S, 10.99. IR (KBr pellet, cm–1): 3378 ν(O–H); 2998 ν(N–H); 1663 19 
ν(C=O); 1561 ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 12.11 (s, 1H,–OH), 10.86 (s, 1H, 20 
NH), 8.86 (s, 1H, HC=N–), 7.92–6.98 (m, 6H, aromatic), 4.06 (m, 2H, –OCH2), 1.35 (t, 3H, –21 
CH3). 13C NMR (100 MHz, DMSO-d6): δ 167.02 (CO–N), 156.23 (N=CH–), 151.52–115.23 22 
(10C, aromatic), 66.34 (–OCH2), 16.52 (–CH3).    23 
H2L4: Yield: 74%. Anal. calcd. for C17H15N3O2: C, 69.61; H, 5.15; N, 14.33. Found: C, 69.24; 24 
H, 5.44; N, 14.41. IR (KBr pellet, cm–1): 3389 ν(O–H); 2988 ν(N–H); 1653 ν(C=O); 1569 25 
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ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 12.53 (s, 1H,–OH), 12.41 (s, 1H, NH), 9.49 (s, 1H, 1 
HC=N–), 8.85–7.24 (m, 10H, aromatic). 13C NMR (100 MHz, DMSO-d6): δ 166.89 (CO–N), 2 
160.41 (N=CH–), 151.52–114.91(13C, aromatic). 3 
Synthesis of (1) 4 
[MoO2(acac)2]  was added to an refluxing solution of H2L1 (1:1 ratio) taking methanol as the 5 
solvent. The reaction mixture was refluxed for 4 h after which the solution turned dark-orange. 6 
The resultant reaction mixture was filtered and kept for crystallization. After 2-3 days of slow 7 
evaporation, a fine orange crystalline complex, [MoVIO2L1(Q)] (where, Q = MeOH) (1), 8 
suitable for X-ray crystallographic measurements was obtained.  9 
[MoVIO2L1(Q)] (1): Yield: 66%. Anal. Calcd for C15H16MoN2O7: C, 41.68; H, 3.73; N, 6.48; 10 
Found: C, 41.66; H, 3.79; N, 6.51. IR (KBr pellet, cm−1): 1584 ν(C=N), 945, 934 ν(Mo=O). 11 
UV−Vis (DMSO): λmax, nm (ε, dm3 mol−1 cm−1): 442 (1011), 310 (9758). 1H NMR (400 MHz, 12 
DMSO-d6): δ (ppm): 8.89 (s, 1H, HC=N–), 7.96–6.71 (m, 6H, aromatic), 4.14 (s, 1H, –HO 13 
(enolic)), 4.096 (m, 2H,   –OCH2), 3.18 (d, 3H, –OCH3), 1.35 (t, 3H, –CH3). 13C NMR (100 14 
MHz, DMSO-d6): δ (ppm): 161.98 (CO=N), 156.32 (N=CH–), 149.78–112.98 (10C, aromatic), 15 
64.82 (–OCH2), 49.07 (–OCH3), 15.19 (–CH3). 16 
Synthesis of mixed-ligand complexes (2–4) 17 
The precursor [MoO2(acac)2] was added to an refluxing methanolic solution of H2L2-4 in a 18 
equimolar ratio and a dark-orange solution was obtained in each case after 1 h of reflux. Then 19 
a stoichiometric amount of the co-ligand imidazole (Q) was added.  Each solution was filtered 20 
after a reflux period of ca 3 h. After slow evaporation of the filtrate over 4 days, orange-red 21 
crystals of [MoVIO2L2-3(Q)] (2 and 3) and [MoVIO2L4(Q)]2(H2O) (4), were obtained and washed 22 
thoroughly with methanol and dried.  23 
[MoVIO2L2(Q)] (2): Yield: 68%. Anal. Calcd for C23H22MoN4O5: C, 52.28; H, 3.82; N, 10.60. 24 
Found: C, 52.17; H, 3.88; N, 10.71. IR (KBr pellet, cm−1): 1567 ν(C=N); 922, 906 ν(Mo=O). 25 
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UV−Vis (DMSO): λmax, nm (ε, dm3 mol−1 cm−1): 441 (1300), 307 (10124). 1H NMR (400 1 
MHz, DMSO-d6): δ (ppm):  9.06 (s, 1H, HC=N–), 8.83–7.02 (m, 13H, aromatic), 4.12 (m, 2H, 2 
–OCH2), 1.38 (t, 3H, –CH3). 13C NMR (100 MHz, DMSO-d6): δ (ppm): 170.78 (CO=N), 3 
157.32 (N=CH–), 150.10–119.24 (19C, aromatic), 64.83 (–OCH2), 15.22 (–CH3). 4 
[MoVIO2L3(Q)] (3): Yield: 64%. Anal. Calcd for C17H16MoN4O5S: C, 42.16; H, 3.33; N, 5 
11.57; S, 6.62. Found: C, 42.11; H, 3.39; N, 11.58; S, 6.71. IR (KBr pellet, cm−1): 1557 6 
ν(C=N); 928, 906 ν(Mo=O). UV−Vis (DMSO): λmax, nm (ε, dm3 mol−1 cm−1): 442 (1425), 7 
322 (8986). 1H NMR (400 MHz, DMSO-d6): δ (ppm):  8.87 (s, 1H, HC=N–), 7.86–6.99 (m, 6 8 
H, aromatic), 4.07 (m, 2H, –OCH2), 1.34 (t, 3H, –CH3). 13C NMR (100 MHz, DMSO-d6): δ 9 
(ppm): 165.90 (CO=N), 155.69 (N=CH–), 150.27–119.71 (10C, aromatic), 65.22 (–OCH2), 10 
15.19 (–CH3). 11 
[MoVIO2L4(Q)]2 (H2O) (4): Yield: 61%. Anal. Calcd for C40H32Mo2N10O9: C, 48.60; H, 3.26; 12 
N, 14.17. Found: C, 48.66; H, 3.21; N, 14.18. IR (KBr pellet, cm−1): 1557 ν(C=N); 928, 906. 13 
ν(Mo=O). UV−Vis (DMSO): λmax, nm (ε, dm3 mol−1 cm−1): 453 (2983), 328 (9456), 260 14 
(10531). 1H NMR (400 MHz, DMSO-d6): δ (ppm):  9.82 (s, 1H, HC=N–), 8.79–7.03 (m, 13 H, 15 
aromatic). 13C NMR (100 MHz, DMSO-d6): δ (ppm): 166.87 (CO=N), 161.33 (N=CH–), 16 
154.31–112.00 (16C, aromatic). 17 
Single crystal X-ray structure determination 18 
Crystal data and refinement details for 1-4 are collated in Table 1.  Intensity data (100 K) for 19 
1-3 were measured on a Rigaku/Oxford Diffraction XtaLAB Synergy diffractometer (Dualflex, 20 
AtlasS2) fitted with CuKα radiation (λ = 1.54178 Å) while those for 4 were measured on an 21 
Agilent Technologies SuperNova Dual CCD with an Atlas detector fitted with Mo Kα radiation 22 
(λ = 0.71073 Å).  Data reduction and empirical absorption corrections, based on a gaussian (1-23 
3 [80]) or multi-scan (4 [81]) techniques, were applied.  The structures were solved by direct 24 
methods [82] and refined on F2 with anisotropic displacement parameters and C-bound H 25 
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atoms in the riding model approximation [83].  For 1, the oxygen-bound H atoms were refined 1 
with a distance restraint O‒H = 0.84±0.01 Å while for 2-4, the nitrogen-bound H atoms were 2 
refined with a distance restraint N‒H = 0.88±0.01 Å.  A weighting scheme of the form w = 3 
1/[σ2(Fo2) + (aP)2 + bP] where P = (Fo2 + 2Fc2)/3) was introduced in each refinement.  For 2, 4 
the maximum and minimum residual electron density peaks of 2.69 and 1.03 eÅ-3, respectively, 5 
were located 0.84 and 0.72 Å from the Mo atom, respectively.  This is an artefact of the data 6 
and not indicative of unresolved chemistry.  For 3, owing to poor agreement, the (1 1 3) 7 
reflection was omitted from the last cycles of refinement.  The thienyl ring was disordered over 8 
two co-planar, anti-parallel orientations with the site occupancy factor of the major component 9 
refining to 0.875(4).  The C9, C11 and C12 positions were common to both components and 10 
were refined anisotropically. The S1 and C10 atoms of the major component were refined 11 
anisotropically but those for the minor component were refined isotropically.  The C9–C10 and 12 
C10–C11 bond lengths of the minor component were constrained to be equivalent to those for 13 
the major component.  Finally, the absolute structure was determined based on differences in 14 
Friedel pairs included in the data set.  In 4, there is half a water molecule disordered over two 15 
positions about a centre of inversion; the O–H distances were fixed at 0.84 Å.  There is some 16 
evidence for disorder in the imidazole ring as seen in the shapes of the displacement ellipsoids.  17 
However, an alternate position was not discerned for this molecule. The molecular structure 18 
diagrams were generated by ORTEP for Windows [84] and the packing diagrams with 19 
DIAMOND [85].  Additional data analysis was made with PLATON [86]. 20 
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Table 1. Crystal data and refinement details for complexes 1-4. 1 
Complex 1 2 3 4 2 
Formula C15H16MoN2O7 C23H20MoN4O5 C17H16MoN4O5S C40H32Mo2N10O9 3 
Formula weight 432.24 528.37 484.34 988.64 4 
Crystal colour light-brown light-brown light-brown red-brown 5 
Crystal size/mm3 0.08 × 0.10 × 0.11 0.03 × 0.04 × 0.08 0.13 × 0.16 × 0.17 0.10 × 0.25 × 0.30 6 
Crystal system Triclinic Triclinic Orthorhombic Monoclinic 7 
Space group P1¯ P1¯ P212121 P21/n 8 
a/Å 10.2487(2) 7.98370(10) 8.09320(10) 9.4568(2) 9 
b/Å 12.2450(2) 9.8896(2) 12.0195(2) 13.0259(2) 10 
c/Å 13.2350(4) 13.9897(2) 19.6535(2) 15.9707(3) 11 
α/° 90.236(2) 91.2290(10) 90 90 12 
β/° 97.070(2) 90.0870(10) 90 106.320(2) 13 
γ/° 90.6870(10) 104.721(2) 90 90 14 
V/Å3 1648.16(7) 1068.03(3) 1911.82(4) 1888.05(6) 15 
Z 4 2 4 2 16 
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Dc/g cm-3   1.742 1.643 1.683 1.739 1 
F(000)   872 536 976 996 2 
µ(MoKα)/mm-1   6.901 5.410 6.972 0.738 3 
Measured data   39123 25342 13028 9628 4 
θ range/°   3.4 – 67.1 3.2 – 67.1 4.3 – 67.1 2.3 – 29.3 5 
Unique data      5893 3817 3399 4403 6 
Observed data (I ≥ 2.0σ(I)) 5652 3707 3386 3665 7 
No. parameters    461 302 266 283 8 
R, obs. data; all data 0.022; 0.059 0.037; 0.096 0.019; 0.047 0.031; 0.074 9 
a; b in weighting scheme 0.039; 1.022 0.052; 2.843 0.030; 0.698 0.037; 2.383 10 
Rw, obs. data; all data 0.023; 0.600 0.038; 0.097 0.019; 0.047 0.043; 0.083 11 
Range of residual electron 12 
density peaks/eÅ-3 -0.74 – 0.42 -1.03 – 2.69 -0.65 – 0.26 -0.57–0.6313 
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DNA binding experiments 1 
Absorption spectral studies 2 
Interaction of the dioxidomolybdenum(VI) complexes with CT-DNA was studied through UV-3 
Vis absorption titration experiments. A fixed concentration of the metal complex (25 μM) was 4 
titrated against a variable concentration of CT-DNA (0 to 110 μM) in 50 mM Tris-HCl buffer 5 
(pH 8.0). Readings were recorded after each addition of CT-DNA (10 μM) to the metal. Data 6 
were then calculated using the following equation (Eqn 1) to obtain the binding constant Kb 7 
[37,66,73] 8 
[𝐷𝐷𝐷𝐷𝐷𝐷] ε𝑎𝑎− ε𝑓𝑓 = [𝐷𝐷𝐷𝐷𝐷𝐷] ε𝑏𝑏− ε𝑓𝑓 +  1 𝐾𝐾𝑏𝑏(ε𝑏𝑏− ε𝑓𝑓  )     (Eqn 1) 9 
where [DNA] is represents the concentration of CT–DNA base pairs whereas the parameters 10 
εa, εf and εb correspond to the apparent extinction co-efficient for the complexes, i.e. 11 
Abs/[complex] in the presence and absence of CT–DNA and to fully bound DNA, respectively. 12 
A plot of [DNA]/(εa − εf ) vs [DNA] gave a slope of 1/(εa − εf ) and the intercept equal to 13 
(1/Kb)(εb − εf). Thus, the ratio of the slope to the intercept gives the value of binding constant 14 
Kb. Binding affinity of the ligands towards CT-DNA was studied in a similar fashion by taking 15 
a fixed concentration of ligand [25 μM in 50 mM Tris-HCl buffer (pH 8.0)] against variable 16 
CT-DNA concentrations ranging from 0 to 100 μM. 17 
Competitive DNA binding by Fluorescence measurements  18 
To understand the exact mode of binding of the complexes with CT-DNA, competitive DNA 19 
binding experiments with three fluorescent dyes namely 4′,6-diamidino-2-phenylindole 20 
(DAPI), methyl green (MG) and ethidium bromide (EB) was carried out.  Among these 21 
fluorescent dyes EB tends to bind DNA through intercalation whereas DAPI and MG bind to 22 
the minor and major grooves, respectively [66,87,88]. This was studied by measuring the 23 
fluorescence emission intensities of DAPI, MG and EB bound CT-DNA at 455 nm (excitation 24 
358 nm), 663 nm (excitation 600 nm) and 597 nm (excitation 520 nm)  with an increasing 25 
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amount of the complex concentration (0−100 μM) in a Fluoromax 4P spectrofuorimeter 1 
(Horiba Jobin Mayer, USA). 2 
In vitro cytotoxic activity 3 
Cell cultures 4 
HT-29 (colon cancer) and HeLa (cervical cancer) cells were obtained from National Centre of 5 
Cell Science (NCCS), Pune, India. The cells were maintained in DMEM supplemented with 6 
10% FBS and penicillin–streptomycin solution at 37 °C in a 95% humidified and 5% CO2 7 
incubator. Working concentrations of 5, 10, 50 and 100 μg/ml were prepared in culture medium 8 
from a stock concentration of 3 mg/ml of each complex. Also, the concentration of DMSO was 9 
maintained at less than 0.1% (v/v) in all experiments to avoid any toxicity due to DMSO. 10 
MTT assay 11 
For the MTT assay, both HT-29 and HeLa cells were harvested from their maintenance cultures 12 
in logarithmic phase. Following cell counting in a hemocytometer, cells were seeded into a 96 13 
well plate, at a concentration of 1 × 104 cells per well. These cells were then incubated with 14 
various concentrations of the test compounds for 48 h. The result of the treatment of the 15 
complexes on viability of the cancer cells was studied using MTT dye reduction assay by 16 
measuring the optical density at 595 nm using micro-plate reader spectrophotometer (Perkin-17 
Elmer 2030) [78]. 18 
DAPI staining 19 
Nuclear morphology of the cancer cells in response to treatment with the complexes was 20 
studied through DAPI staining by following a reported procedure [68]. Treated and untreated 21 
cells were fixed with 4 % formaldehyde for 15 min followed by staining with 1 μg/ml DAPI 22 
for 5 min at 37 °C. The cells were then washed with PBS and finally examined by fluorescence 23 
microscopy (Olympus IX 71) to determine if any nuclear condensation or fragmentation had 24 
occurred, indicating the cells underwent apoptosis. 25 
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Results and discussion 1 
Synthesis 2 
In the present study, four new mixed ligand dioxidomolybdenum(VI) [MoVIO2L1-3(Q)] (1‒3), 3 
[MoVIO2L4(Q)]2 (H2O) (4) [where Q = MeOH for 1 and imidazole for 2‒4] complexes were 4 
synthesized from four differently substituted ONO donor aroylhydrazone ligands, H2L1–4, as 5 
indicated in Scheme 1. The complexes were successfully characterized by UV−vis, IR, NMR, 6 
cyclic voltammetry and the molecular and crystal structures were determined by X-ray 7 
crystallography. The aqueous phase stability of the complexes has been investigated by time-8 
dependent UV-vis spectroscopy for 72h and a representative spectrum, for 1, is depicted in Fig. 9 
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Scheme 1. Schematic pathway for the formation of [MoVIO2L1-3(Q)] (1‒3), 12 
[MoVIO2L4(Q)]2 (H2O) (4).  13 
Spectral characteristics 14 
 
 
15 
 
Detailed spectral (IR, UV-Vis and NMR) data of H2L1−4 and their respective corresponding 1 
complexes (1–4) are given in the Experimental section. Infrared spectra of the ligands display 2 
three broad band in the ranges 3392–3336, 3042–2988 and 1663–1653 cm−1 which are 3 
attributed to ν(O–H) stretching of hydroxy group of 2-hydroxy aldehyde, ν(N–H) stretching 4 
and ν(C=O) stretching, respectively. Disappearance of characteristic bands of O–H, N–H and 5 
C=O in the complex spectra indicates the coordination of the ligands to the metal centre in their 6 
phenolate form after enolization [77,89]. Also, the presence of two new stretching bands in the 7 
range 928–906 cm−1 in the complex spectra indicate the dioxido nature (Mo=O) of the 8 
complexes. 9 
Electronic spectra of 1–4 were recorded in DMSO. The spectra of all the complexes were 10 
similar in nature and as a representative UV-Vis spectrum of 4 is depicted in Fig. 1. Strong 11 
absorptions observed in the range 453–442 nm are assignable to ligand-to-metal charge transfer 12 
(LMCT) transitions whereas bands in the higher energy region 328–260 nm are likely to be 13 
due to ligand centred transitions [75,77]. Moreover, the presence an extra peak in the complex 14 
spectra at 453–442 nm region, as compared to that of the ligand suggests coordination of the 15 
ligand upon complexation.  16 
 17 
Fig. 1.  UV-vis spectra of [MoVIO2L4(Q)]2.H2O (4) in DMSO employing the complex 18 
concentration 1.3× 10−4 M. 19 
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The 1H and 13C NMR data of H2L1–4 and their corresponding complexes (1–4) were recorded 1 
in DMSO-d6. The ligand spectra exhibit two singlets in the ranges δ = 12.53–12.02 and 12.41–2 
10.62 ppm due to the presence of phenolic –OH and NH protons, respectively. The 3 
disappearance of these two resonances in the spectra of the complexes confirms their 4 
deprotonation and coordination to the central metal atom. The presence of a singlet resonance 5 
for the ligands and complexes in the region δ = 9.82–8.65 ppm is attributed to the azomethine 6 
–CH proton. One quartet in the range δ = 4.12–4.06 ppm and a triplet in the range δ = 1.38–7 
1.34 ppm is observed for H2L1‒3 and their complexes 1–3 due to the presence of the ethoxy 8 
group in the ligand moiety. On the other hand, due to presence of a coordinated MeOH 9 
molecule, complex 1 exhibits an OH (enolic) resonance at δ = 4.14 ppm and a –OCH3 10 
resonance at δ = 4.09 ppm. Moreover, the increased number of resonances in the aromatic 11 
region for complexes 2–4 as compared to H2L2‒4 indicates the binding of co-ligand imidazole 12 
to the metal atom. 1H NMR spectra of all the complexes (1–4) are given in Figs SI 2–5. 13 
In the 13C NMR spectra of 1–4, signals for the aromatic carbons are found in the downfield 14 
region in the range δ = 170.78–112.98 ppm. Signals for the aliphatic carbons of –OCH2 and –15 
CH3 of 1–3 appear in the range δ = 65.22–15.19 ppm. Whereas complex 1 exhibits an additional 16 
aliphatic carbon signal at δ = 49.07 due to the presence of methanolic –OCH3 carbon. 17 
Electrochemical Properties 18 
Electrochemical properties of the complexes have been studied by cyclic voltammetry in 19 
DMSO solution. Voltammograms of all the complexes show a similar type of redox property 20 
and representative voltammograms for 1 and 2 are depicted in Fig. 2. An irreversible single 21 
electron reductive response is observed in the cathodic region at a potential window −0.74 to 22 
−0.69 V that can be attributed to the Mo(VI) → Mo(V) reduction [68,74,76,90]. Also, a single 23 
electron irreversible cathodic response in the region −1.04 to −0.95 V and anodic response at a 24 
potential window 0.44 to 0.12 V are observed that may be attributed to the ligand centered 25 
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reduction and oxidation, respectively. The cyclic voltammetry experiments of the ligands have 1 
also been performed and a representative voltammogram of H2L1 is shown in Fig. SI 6. The 2 
redox potential data of all the complexes are listed in Table 2 and the single electron processes 3 
were also confirmed by comparing the current height to the standard ferrocene−ferrocenium 4 
couple under identical experimental conditions.  5 
 6 
 7 
Fig. 2. Cyclic voltammogram of [MoVIO2L1(Q)] (1) (a) and [MoVIO2L2(Q)] (2) (b) in 8 
DMSO. 9 
Table 2. Cyclic voltammetric resultsa for 1–4 at 298 K in DMSO. 10 
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Complex EcP (V) EaP (V) 
1 −0.74, −0.99 0.12 
2 −0.69, −1.04 0.39 
3 −0.71, −1.04 0.21 
4 −0.70, −0.95 0.44 
a In DMSO at a scan rate 100 mV s-1. Where EcP and EaP are cathodic and anodic peak 1 
potentials vs. SCE, respectively. 2 
Molecular structures 3 
The molecular structures of 1-4 have been established by X-crystallography and selected 4 
geometric parameters are collated in Table 3.  The crystallographic asymmetric unit of 1 5 
comprises two independent molecules, the first of which is shown in Fig. 3(a) and the second 6 
in Fig. SI 7(a); the molecules have very similar conformations as seen in the overlay diagram 7 
of Fig. SI 7(b).  The molecules of 1 comprise a Mo(=O)2 core complexed by a di-negative, 8 
tridentate Schiff base ligand, via the phenoxide-O1, amide-O4 and imine-N1 atoms, with the 9 
sixth site occupied by an O-bound methanol molecule.  The oxo groups are cis, the phenoxide-10 
O1 and amide-O4 atoms trans, the oxido-O2 atom, occupying a position in the approximate 11 
plane of the tridentate ligand, is trans to the imine-N1 atom, and the oxido-O3 atom is trans to 12 
the methanol-O6 atom.  The resulting NO5 donor set is based on an octahedron.  The mode of 13 
coordination of the tridentate ligand gives rise to five- and six-membered chelate rings and it 14 
is the acute bite angles subtended by these (Table 3) that are responsible for the major 15 
distortions from the ideal octahedral geometry. 16 
The Mo-O1(phenoxide) bond length of 1.9170(14) Å is considerably shorter than the Mo-17 
O4(amide) bond length of 2.0299(14) Å, an observation correlated with delocalisation of π-18 
electron density over the amide chromophore.  While the differences in the geometric 19 
 
 
19 
 
parameters involving the lighter atoms are small, there are discernible and consistent trends to 1 
substantiate this observation.  Thus, the C8–O4 bond length is significantly shorter than the 2 
C1–O1 bond, i.e. 1.312(2) Å cf. 1.351(2) Å, and conversely, there is an indication the formally 3 
double C8–N2 bond is longer, at 1.309(3) Å, than the C7–N1 imine bond, at 1.295(3) Å, the 4 
experimental errors notwithstanding.  In the same way, there is an indication that the Mo–5 
O2(oxido) bond length is longer than the Mo–O3(oxido) bond, i.e. 1.7083(13) Å cf. 1.6956(15) 6 
Å, with the former being trans to the imine-N1 atom, and the latter trans to the methanol-O6 7 
atom. Delete to make the text shorter? I obviously think this is important but, perhaps it is too 8 
detailed for the Journal’s liking 9 
As mentioned above, the five-membered, i.e. Mo,O4,N1,N2,C8, and six-membered, i.e. 10 
Mo,O1,C1,C6,C7,N1, chelate rings are formed upon complexation of the di-anion.  The five-11 
membered ring is practically planar, exhibiting a r.m.s. deviation for the five atoms of 0.0087 12 
Å.  By contrast, the best description for the six-membered ring is that of an envelope whereupon 13 
the Mo1 atom lies 0.504(2) Å out of the plane of the five remaining atoms, which exhibit a 14 
r.m.s. deviation of 0.0435 Å.  The dihedral angle between the least-squares planes through the 15 
chelate rings is 7.82(9)°, indicating the backbone of the tridentate ligand is approximately 16 
planar.  The appended furanyl ring makes a dihedral angle of 6.11(13)° with the five-membered 17 
chelate ring, again indicating a co-planar arrangement; the dihedral angle between the outer 18 
rings is 5.26(14)°. 19 
 20 
 
 
20 
 
 1 
Fig. 3.  Molecular structure of the first independent molecule comprising the asymmetric unit 2 
of 1, showing the atom labelling scheme and anisotropic displacement parameters at the 70% 3 
probability level. 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
Table 3. Selected geometric parameters (Å, °) for complexes 1-4. 15 
Complex 1 1 a 2 3 4 16 
(Y = O6) (Y = O6) (Y = N3) (Y = N3)         (Y = N3) 17 
Parameter 18 
Mo‒O1 1.9170(14) 1.9242(14) 1.947(2) 1.947(2)        1.9367(17) 19 
Mo‒O2 1.7083(13) 1.7068(13) 1.714(3) 1.709(2)        1.7064(18) 20 
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Mo‒O3 1.6956(15) 1.6966(15) 1.701(3) 1.698(2)        1.7040(19) 1 
Mo‒O4 2.0299(14) 2.0351(14) 2.010(2) 2.016(2)        2.0169(19) 2 
Mo‒N1 2.2457(16) 2.2423(16) 2.231(3) 2.248(2)        2.228(2) 3 
Mo‒Y 2.3207(14) 2.3221(14) 2.347(3) 2.330(2)        2.336(2) 4 
O1‒C1 1.351(2) 1.347(2) 1.357(4) 1.353(4)        1.343(3) 5 
O4‒C 1.312(2) 1.314(2) 1.327(4) 1.322(4)        1.320(3) 6 
N1‒N2 1.395(2) 1.391(2) 1.403(4) 1.393(3)        1.403(3) 7 
N1‒C 1.295(3) 1.296(3) 1.275(5) 1.296(4)        1.291(3) 8 
N2‒C 1.309(3) 1.308(3) 1.293(5) 1.307(4)        1.297(3) 9 
O1‒Mo‒O4 150.17(6) 149.39(6) 149.59(10) 149.33(8)      148.77(8) 10 
O1‒Mo‒N1 81.27(6) 80.85(6) 81.66(10) 81.61(9)        80.41(7) 11 
O2‒Mo‒O3 106.63(7) 105.78(7) 105.94(13)        104.69(10)   106.42(10) 12 
O2‒Mo‒N1 157.75(6) 157.86(6) 161.21(12) 163.61(9)       161.96(9) 13 
O3‒Mo‒Y 169.24(6) 171.72(6) 169.43(12) 170.54(10)     168.97(9) 14 
O4‒Mo‒N1 72.09(6) 71.49(5) 71.77(10) 71.93(9)          72.25(7) 15 
a The parameters for the second independent molecule in 1 follow the numbering scheme 16 
shown in Fig. 3(a). 17 
 18 
The second molecule comprising the asymmetric of 1 adopts essentially the same molecular 19 
structure and trends as for the first.  The envelope conformation for the six-membered ring is 20 
more pronounced with the Mo2 atom lying 0.603(2) Å out of the plane of the five remaining 21 
atoms (r.m.s. deviation = 0.0367 Å).  The dihedral angle between the chelate rings is 9.45(9)°, 22 
between the five-membered and furanyl rings 3.02(12)° and between the outer rings 23 
13.67(12)°, mirroring the first independent molecule. and/or delete this? 24 
The molecular structures of 2 and 3 are closely related to that of 1 in that the methanol molecule 25 
has been replaced by an imidazole in each case, and with the furanyl substituent in 1 replaced 26 
by naphthyl (2) and thienyl (3), leading to cis-N2O4 distorted octahedral geometries.  In 4, 27 
imidazole is still present but both peripheral aromatic systems differ, being based on naphthyl 28 
and 4-pyridyl; 4 was isolated as a mono-hydrate.  The molecular structures of 2-4 are shown in 29 
 
 
22 
 
Figs 4(a)-(c) and selected geometric parameters are given in Table 3.  The molecular geometry 1 
and trends in geometric parameters for 2-4 match closely those established for 1.  The notable 2 
exception is the equivalence of the Mo-O(oxido) bond lengths in 4.  The conformations of the 3 
chelate rings also match those seen in 1; geometric data are given in Table SI 1.  Across the 4 
series, the five-membered rings are most planar in the structures of 2 and 3, and in terms of the 5 
deviations of the Mo atoms in the envelope conformations for the six-membered rings, these 6 
are intermediate to those seen in the independent molecules of 1.  In the same way, the dihedral 7 
angles between the chelate rings in each of 2-4 are intermediate to those seen in 1.  The dihedral 8 
angles between the outer aromatic rings is greater than those in 1 in the case of 2, i.e. 9 
14.77(11)°, or smaller, in 3 (2.13(17)°) and 4 (4.77(19)°). 10 
 11 
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Fig. 4.  Molecular structures of (a) 2, (b) 3 (minor component of the disordered thienyl ring is 1 
omitted) and (c) 4 (water molecule omitted) showing atom labelling schemes and displacement 2 
parameters at the 50, 70 and 50% probability levels, respectively. 3 
Molecular packing 4 
The geometric parameters associated with the specified intermolecular interactions discussed 5 
in the following are collated in the respective captions of Figs 5 and SI 8-11.  In the molecular 6 
packing of 1, each independent molecule self-associates into a dimeric aggregate via hydroxy-7 
O–H…N(imine) hydrogen bonds as shown in Fig. 5(a) and Fig. SI 8(a) for the first and second 8 
independent molecules, respectively.  The supramolecular dimers are assembled into a layer in 9 
the ab-plane via furanyl- and imine-C–H…O(oxido) interactions occurring between Mo1- and 10 
Mo2-containing molecules, Fig. SI 8(b).  The layers inter-digitate along the c-axis with the 11 
closest atom-to-atom contact being a weak methyl-C–H…O(oxido) contact, Fig. SI 8(c). 12 
 13 
Fig. 5.  Supramolecular aggregates in the crystals of 1-4 sustained by hydrogen bonding (shown 14 
as orange dashed lines): (a) dimer in 1 stabilised by hydroxy-O–H…N(imine) hydrogen bonds 15 
[O6–H6o…N2i: H6o…N2i = 1.907(19) Å, O6…N2i = 2.732(2) Å with angle at H6o = 168(2)° for 16 
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symmetry operation (i) 2-x, 2-y, 1-z], (b) dimer in 2 mediated by imidazole-N–H…O(phenoxide, 1 
ethoxy) hydrogen bonds [N4–H4n…O1ii: H4n…O1ii = 2.28(3) Å, N4…O1ii = 2.953(4) Å with 2 
angle at H4n = 133(4)°; N4–H4n…O5ii: H4n…O5ii  = 2.26(3) Å, N4…O5ii = 2.983(4) Å with angle 3 
at H4n = 139(4)° for (ii) 1-x, 1-y, 1-z], (c) helical chain in 3 sustained by imidazole-N–4 
H…O(phenoxide, ethoxy) hydrogen bonds [N4–H4n…O1iii: H4n…O1iii = 2.19(3) Å, N4…O1iii = 5 
2.947(3) Å with angle at H4n  = 144(3)°; N4–H4n…O5iii: H4n…O5iii = 2.23(3) Å, N4…O5iii = 6 
2.927(3) Å with angle at H4n = 136(3)° for (iii) -½+x, ½-y, 1-z] and (d) detailed view and seven-7 
molecule aggregate in 4 sustained by imidazole-N–H…O(water), water-O–H…O(oxido) and 8 
water-O–H…N(pyridyl) hydrogen bonds [O1w–H1w…O3iv: H1w…O3iv = 2.30 Å, O1w…O3iv = 9 
3.028(5) Å with angle at H1w =145°;O1w–H2w…N5v: H2w…N5v = 1.91 Å, O1w…N5v = 10 
2.708(5) Å with angle at H2w =158°; N4–H4n…O1w: H4n…O1w = 1.93(2) Å, N4…O1w = 11 
2.795(7) Å with angle at H2w = 170(4)°; N4–H4n…O1wvi: H4n…O1wvi = 2.16(3) Å, N4…O1wvi 12 
= 3.016(7) Å with angle at H4n = 166(5)° for (iv) ½-x, -½+y, ½-z, (v) ½+x, ½-y, -½+z and (vi) 13 
-x, -y, -z]; the latter are shown as blue dashed lines.  For reasons of clarity, non-participating 14 
hydrogen atoms are removed. {full page image} 15 
Centrosymmetric supramolecular dimers are also found in the crystal of 2.  Here, the imidazole-16 
N–H atom is bifurcated forming hydrogen bonds with the phenoxide-O1 and ethoxy-O5 atoms 17 
to form a five-membered {…H…OC2O} synthon, Fig. 5(b).  Each component of the dimer is 18 
connected into a layer in the ab-plane by naphthyl- and imidazole-C–H…O(oxido) and 19 
methylene-C–H…O(amide) interactions resulting in a double-layer, Fig. SI 9(a).  Alternatively, 20 
the packing can be described as comprising supramolecular layers sustained by the 21 
aforementioned C–H…O interactions, see Fig. SI 9(b), which are clipped into a double-layer by 22 
the N–H…O hydrogen bonds.  The double-layers stack along the c-axis direction without 23 
directional interactions between them. 24 
In the molecular packing of 3, analogous imidazole-N–H…O(phenoxide, ethoxy) hydrogen 25 
bonding and five-membered {…H…OC2O} synthons are formed as seen for 2 but, in this case, 26 
these extend to form a one-dimensional supramolecular chain as shown in Fig. 5(c).  The chain 27 
is orientated along the a-axis and has a helical topology, being propagated by screw (21) 28 
symmetry; additional stability to the chain is provided by imidazole-C–H…O(oxido) 29 
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interactions.  Chains are connected laterally to form a supramolecular layer in the ab-plane via 1 
phenyl-C–H…O(oxido) contacts, see Fig. SI 10(a).  The most prominent points of contact 2 
between layers along the c-axis direction are S…O secondary bonding interactions (S1…O2i = 3 
3.068(2) Å for (i): 1-x, ½+y, ½-z).  Such interactions are well-known but, are gaining 4 
increasing recognition for their importance in stabilising molecular packing [91-93]; a view of 5 
the unit cell contents is shown in Fig. SI 10(b). 6 
The inclusion of a water molecule, albeit statistically disordered about a centre of inversion, 7 
provides the cohesion to the molecular packing in the crystal of 4.  The imidazole-N–H forms 8 
hydrogen bonds to each of the disordered water-O atoms, with the water-O–H donor atoms 9 
forming hydrogen bonds to oxido-O and pyridyl-N atoms.  In this way, six molecules of 4 are 10 
assembled about the water molecule.  As there are peripheral oxido, imidazole and pyridyl 11 
residues in the seven-molecule aggregate, a three-dimensional architecture is generated as 12 
illustrated in Fig. SI 11. 13 
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DNA Binding Studies 1 
Absorption spectroscopic studies 2 
Applying spectral techniques, the DNA binding affinity of the complexes 1–4 to CT-DNA was 3 
studied and the equilibrium binding constant (Kb) of the complexes to CT-DNA was established 4 
(Table 4 and Fig. 6). Complexes 1–4 exhibit absorption bands in the regions 450–400, 340–300 5 
that are attributed to L–Mo(dπ) and LMCT transitions while bands at 260–290 nm are due to 6 
intraligand transitions [76]. On adding CT-DNA, complex 1 showed a hyperchromic shift in the 7 
L–Mo(dπ) LMCT region whereas hypochromic shifts were observed in both the 340–300 and 260–8 
290 nm ranges; Fig. SI 12(a).  For 2–4, hypochromic shifts were found in all three ranges; Fig. 6 9 
and Figs SI 12(b)–(c). Both the hyperchromic and hypochromic shifts indicate the interaction of 10 
the CT-DNA with the dioxidomolybdenum complexes. The hyper chromic shift observed may be 11 
either due to electrostatic binding of the complexes to the DNA i.e. the external contact or to the 12 
major and minor grooves of DNA [94,95]. The observed hypochromic shifts may be due to the 13 
interaction between the electronic states of ligand chromophores and the DNA bases [96-98]. The 14 
hypochromism or hyperchromism observed in these cases were used to estimate the binding 15 
strength of the complexes to the CT-DNA. For all complexes, the 260–290 nm range showed a 16 
significant hypochromism which may be due to the higher binding affinity towards CT-DNA in 17 
the lower wavelength region. The equilibrium binding constant (Kb) between CT-DNA and each 18 
of the complexes 1–4 was calculated using Eqn 1 (given above). 19 
The Kb values are shown in Table 4 and revealed that 4 has the highest binding affinity of 3.57 × 20 
104 M−1 and 1 has the lowest binding affinity of 9.91 × 103 M−1. All complexes display moderate 21 
binding affinity, and the DNA binding strength of the complexes are in the order of 4 > 3 > 2 > 1 22 
(Table 4). There were no significant interactions observed for the ligands towards CT-DNA. 23 
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 1 
Fig. 6.  Electronic absorption spectra of [MoVIO2L4(Q)]2.H2O (4) (25 μM) upon the titration of 2 
CT-DNA (0–110 μM) in 50 mM Tris-HCl buffer (pH 8.0). The arrow indicates the changes in 3 
absorbance intensity with respect to an increase in the concentration of CT-DNA. The inset shows 4 
the linear fit of [DNA]/(εa − εf) vs. [DNA]. 5 
Table 4. CT-DNA Binding parameters for complexes 1-4. 6 
Complex Binding Constant (Kb) 
(M−1) 
Bimolecular rate constant 
(Kq) Value(M−1s−1) 
1 9.91 x 103 6.25 x 1011 
2 1.49 x 104 8.16 x 1011 
3 2.61 x 104 8.58 x 1011 
4 3.57 x 104 1.27 x 1012 
 7 
 8 
 9 
 10 
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Competitive Binding Studies 1 
In an attempt to determine the exact mode of binding of the complexes to CT-DNA, competitive 2 
binding experiments were performed with three fluorescent dyes namely 4′,6-diamidino-2-3 
phenylindole (DAPI), methyl green (MG) and ethidium bromide (EB). Among the three, EB tends 4 
to bind DNA through an intercalation mode whereas DAPI and MG bind the minor and major 5 
grooves, respectively [71]. Titration of EB with increasing concentration of complex show the 6 
quenching of emission intensity of EB bound to CT-DNA at 596 nm with a bathochromic shift. 7 
Thus, the indicated displacement of CT-DNA bound EB by 1-4 shows the binding through 8 
intercalation mode; Fig. 7 and Fig. SI 13. The bimolecular rate constant (Kq) of EB quenching was 9 
determined by following the Stern–Volmer equation and was found to be in the range 6.25 x 1011 10 
− 1.27 x 1012 M−1 s−1 (Table 4). Further, on titration of DAPI bound CT-DNA with increasing 11 
concentration of the complexes, 1 and 3 showed the quenching of emission intensity at 451 nm 12 
with a visible hypsochromic shift, whereas 2 shows a bathochromic shift at the same range in the 13 
emission maxima (Fig. SI 14). From the data it also shows that except for 4, 1-3 bind to CT-DNA 14 
through minor groove binding mode. All complexes exhibited the quenching of ∼53% for 1 15 
followed by ∼56% and ∼62% for 2 and 3, respectively at the fluorescence intensity of 451 nm. 16 
On the other hand, only for complex 4 was a proportionate binding observed on titration with MG 17 
bound CT-DNA. A bathochromic shift is observed at 663 nm, confirming the major groove 18 
binding mode of 4 to CT-DNA (Fig. SI 15).  Hence, these data prove that 1–3 along with an 19 
intercalative mode of binding also bind to CT-DNA through minor groove binding, while 4 binds 20 
through intercalation and in the major groove binding mode.   21 
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 1 
 2 
Fig. 7.  Fluorescence quenching of EB (10 μM) upon the titration of complex 1 (a), 2 (b), 3 (c) and 3 
4 (d) (0–100 μM each). The arrows indicate the decrease in fluorescence intensity with respect to 4 
an increase in the complex concentration; the inset shows the Stern-Volmer plot of the respective 5 
complexes. 6 
In vitro cytotoxic activity 7 
MTT assay 8 
In order to understand the in vitro cytotoxic potential of the synthesized complexes, an MTT assay 9 
was performed against two cancer cell lines HT-29 and HeLa after 48 h of incubation. As the test 10 
complexes were dissolved in DMSO, DMSO was taken as a control experiment so as to identify 11 
the role of solvent in cytotoxicity of the complexes. The results obtained were analyzed through a 12 
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% cell viability profile and expressed in terms of their IC50 values, as depicted in Fig. 8 and Table 1 
5. The aroylhydrazone ligands gave high IC50 values of > 300 μM. Among all the complexes, 4 2 
proved to be the most active against both the cell lines. It was capable of killing almost 50% of the 3 
cell population even at a concentration of 5μg/ml. While the rest of the complexes proved to be 4 
less potent. 5 
Lately, remarkable cytotoxic activities have been reported for molybdenum complexes against 6 
various human cancer cell lines such as A-549(lung cancer), HeLa (cervical carcinoma) and MCF-7 
7 (breast carcinoma) [99-103]. Cytotoxicity of 4 was found to be comparable and even better than 8 
those of some clinical drugs and various previous reports of molybdenum complexes as cytotoxic 9 
agents [104-107]. After analysing both DNA binding and cytotoxicity result it was observed that 10 
among the four complexes, mixed ligand complexes 2‒4 showed better biological activity than 11 
that of complex 1, with a coordinated methanol moelcule. While complex 4 showed the highest 12 
cytotoxicity among the three mixed ligand complexes, probably due to the presence of heterocyclic 13 
2-hydroxy-1-naphthyl functional group attached to the ligand backbone in comparison to 2 and 3 14 
[32,34,108]. 15 
 16 
 17 
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  1 
Fig. 8. Cell viability profile of 1-4 against HT-29 and HeLa after 48h of incubation. Data are 2 
reported as the mean ± SD for n = 4 and *p<0.05 statistical differences between treatment of 3 
complexes 1‒4. 4 
Table 5. IC50 values of 1-4. 5 
Complexes IC50 (μM) IC50 (μM) 
 HT-29 HeLa 
1 177.92 ± 5.41 84.63 ± 3.26 
2 150.89 ± 2.65 162.55 ± 1.54 
3 96.26 ± 0.80 60.64 ± 3.81 
4 20.63 ± 0.71 4.41 ± 0.98 
DAPI Staining 6 
As complex 4 proved to be the most potent among the series, it was logical to study its effect on 7 
the nuclear morphology of both cancer cell lines. This was studied through DAPI staining. Cells 8 
were treated at a concentration of 50 μg/ml of 4 for a period of 24 h, after which they were stained 9 
with DAPI and examined under a fluorescence microscope. From the images (Fig. 9) it could be 10 
deduced that there were condensed chromatin bodies, nuclear blebbings and shrunken morphology 11 
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in the cells treated with 4, whereas there were hardly any condensation observed in the control 1 
image. These phenomena are indicative of apoptosis taking place as the mechanism of cell death 2 
in response to treatment with 4. 3 
Fig. 9. Morphology of HeLa and HT-29 control and cells treated with complex 4 for 24 h. The 4 
cells were stained with DAPI and visualized under fluorescent microscope. Scale bar corresponds 5 
to 20 μm.  6 
Conclusions 7 
In summary, this article presents the synthesis and characterization of four new mixed ligand 8 
dioxidomolybdenum(VI) [MoVIO2L1-3(Q)] (1‒3) and [MoVIO2L4(Q)]2.H2O (4) [where Q = MeOH 9 
for 1 and imidazole for 2‒4] complexes from tridentate arolyazine ligand systems (H2L1–4). Single 10 
crystal X-ray crystallography revealed a distorted octahedral structure in each case. Hydrogen 11 
bonding features in the molecular packing of 1‒4, lead to supramolecular dimeric aggregates in 1 12 
and 2, a helical chain in 3 and a three-dimensional architecture in 4. 13 
The present series of complexes were tested for biological properties in terms of their DNA binding 14 
ability and in vitro cytotoxicity. The study revealed that the complexes bind moderately with CT-15 
DNA via intercalative, minor and major groove modes, while 4 showed the highest binding affinity 16 
compared to the other complexes. Also, the result of an antiproliferative study revealed 4 to be the 17 
most cytotoxic towards both HT-29 and HeLa cancer cell lines among the series. The presence of 18 
HT-29 
Control 
4 HeLa 
Control 
4 
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imidazole as a co-ligand along with a heterocyclic 2-hydroxy-1-naphthyl moiety in the ligand 1 
backbone of 4 may be responsible for a better interaction with DNA as well as cytotoxicity in 2 
comparison to the other complexes. The outcome of the present study will definitely boost further 3 
research on the design of dioxidomolybdenum complexes as metal-based agents for anticancer 4 
studies. 5 
Appendix A. Supplementary material 6 
Crystallographic data for 1-4 reported in this paper have been deposited with the Cambridge 7 
Crystallographic Data Centre (CCDC) as supplementary publication nos 1920543-1920546 for 1-8 
4, respectively.  These data can be obtained free of charge via www.ccdc.cam.ac.uk/getstructures.  9 
Geometric data characterising the chelate rings are given in Table SI 1 and crystallographic 10 
diagrams and details of the specified intermolecular interactions are given in Figs SI 7-11 whereas 11 
the spectra are given in Figs SI 1-6 and SI 12-15. 12 
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